Skip to main content
    M

    MacroGenics Inc (MGNX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.05
    -0.12 (-5.53%)

    Market Cap: $138.68M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    MacroGenics Inc (MGNX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    MacroGenics (MGNX) has a market cap of $138.68M and an enterprise value of $119.33M. It kept -45.36% of revenue as net income over the last 12 months. Revenue grew 22.82% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 13.96% below the market cap, as cash exceeds debt.

    Market Cap$138.68M
    Enterprise Value$119.33M
    Latest price (Nov 17, 2026)$2.05

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 11, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.23% in the quarter ended Sep 30, 2026 and grew 0.79% a year over 2 years.

    Shares Outstanding63.74M
    Shares Change (YoY)+0.81%
    Shares Change (QoQ)+0.23%
    Share Count Growth (2Y CAGR)+0.79%

    Valuation Ratios

    Sales and book value multiples are 1.2x and 5.2x. Its year-end P/S ranged from 0.9x to 12.4x from 2016 to 2025.

    P/S Ratio1.2x
    Forward P/S1.5x
    P/B Ratio5.2x

    Valuation history and multiples

    Price Statistics

    The stock is up 36.67% over 52 weeks and trades 36.73% below its 50-day average.

    Beta (1Y)1.08
    52-Week Change+36.67%
    1-Month Change-38.44%
    3-Month Change-50.84%
    6-Month Change-54.65%
    5-Year Change-87.71%
    10-Year Change-89.87%
    Total Return (1Y)+36.67%
    Total Return (3Y CAGR)-35.35%
    Total Return (5Y CAGR)-36.11%
    Return vs SPY (1Y)+21.56%
    Max Drawdown (1Y)-57.82%
    Max Drawdown (3Y)-95.06%
    Sharpe Ratio (1Y)0.32
    Correlation with SPY (1Y)0.16
    50-Day Average$3.24
    200-Day Average$3.45
    52-Week Range$1.32 to $5.08
    RSI (14 Days)28.8
    Average Volume (20 Days)1.11M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.75x current liabilities, and total debt is 1.18x shareholder equity.

    Current Ratio2.75x
    Quick Ratio2.75x
    Debt / Equity1.18x
    Interest Coverage-4.27x

    Returns and Efficiency

    Return on invested capital is -108.66% over the last 12 months, against a 5-year average of -69.37%.

    Return on Equity (ROE)-204.72%
    Return on Assets (ROA)-16.16%
    Return on Invested Capital (ROIC)-108.66%
    Return on Capital Employed (ROCE)-35.66%
    ROE (5Y Average)-73.31%
    ROA (5Y Average)-32.13%
    ROIC (5Y Average)-69.37%
    Asset Turnover0.39x
    Receivables Turnover1.55x

    Scores

    MGNX has an Altman Z-Score of -5.08, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-5.08
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $113.50M over the last 12 months.

    Revenue$113.50M
    Revenue Growth (YoY)+22.82%
    Gross Profit$113.50M
    Operating Income-$79.69M
    Pretax Income-$142.70M
    Net Income-$51.49M
    EBITDA-$73.84M
    EBIT-$75.41M
    Reported EPS (TTM)-$1.41

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 7.89% of the $318.69M in total assets.

    Cash and Equivalents$49.03M
    Total Debt$29.67M
    Net Cash$19.36M
    Net Cash Per Share$0.30
    Working Capital$187.85M
    Shareholder Equity$25.15M
    Book Value Per Share$0.39
    Total Assets$318.69M
    Total Liabilities$293.53M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.47M of capital spending, operating cash flow left -$41.34M of free cash flow.

    Operating Cash Flow-$39.87M
    Capital Expenditures$1.47M
    Free Cash Flow-$41.34M
    FCF Per Share-$0.65
    Depreciation and Amortization$7.03M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -70.21%.

    Gross Margin100.00%
    Operating Margin-70.21%
    Pretax Margin-125.72%
    Net Margin-45.36%
    EBITDA Margin-65.06%
    EBIT Margin-66.44%
    FCF Margin-36.42%
    Gross Margin (5Y Average)98.55%
    Net Margin (5Y Average)-89.96%

    Growth

    Revenue fell 0.54% a year over 3 years.

    Revenue Growth (3Y CAGR)-0.54%
    Revenue Growth (5Y CAGR)+7.35%
    Book Value Per Share Growth (2Y CAGR)-40.23%
    Tangible Book Per Share Growth (2Y CAGR)-40.23%

    Revenue and profit by year

    Dividends and Yields

    MGNX does not pay a dividend. Its free cash flow yield is -31.63%.

    FCF Yield-31.63%
    Shareholder Yield0.00%

    Peer Position

    Against 4 similar companies, MGNX has the lowest P/S.

    P/S Ratio1.2x vs 7.5x median
    ROIC-108.66% vs 4.62% median
    Revenue Growth (Trailing 4 Quarters, YoY)+22.82% vs -99.11% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -22.15% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-22.15%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MGNX

    What is MGNX's market cap?

    MacroGenics has a market cap of $138.68M. Its enterprise value, which adds debt and subtracts cash, is $119.33M.

    How many shares of MGNX are outstanding?

    MacroGenics has 63.74M shares outstanding. The count is up 0.81% from a year earlier.

    Does MGNX pay a dividend?

    No. MacroGenics does not pay a dividend.

    How much debt does MGNX have?

    MacroGenics has $29.67M of total debt and $49.03M of cash and equivalents, a net cash position of $19.36M.